Plasma cell leukemia is a rare blood cancer where malignant plasma cells spread quickly through the bloodstream. It usually develops from multiple myeloma, another cancer of plasma cells.
Unlike most leukemias, which start in immature blood-forming cells, plasma cell leukemia begins in fully developed plasma cells. These cells normally produce antibodies to fight infections. In plasma cell leukemia, the cancerous plasma cells crowd out healthy blood cells, weakening the immune system.
Plasma cell leukemia accounts for about 0.5% of all leukemia cases, making it extremely rare. The American Society of Clinical Oncology estimates fewer than 500 new cases annually in the U.S.
Plasma cell leukemia falls into two categories:
| Type | Description |
|---|---|
| Primary plasma cell leukemia | Develops de novo without prior plasma cell disorders |
| Secondary plasma cell leukemia | Arises from existing multiple myeloma or similar conditions |
Doctors diagnose plasma cell leukemia through blood tests, bone marrow biopsies, and imaging scans. Common symptoms include fatigue, bone pain, frequent infections, and anemia. The disease progresses rapidly, often within months.
I once observed a case where a patient presented with severe back pain initially attributed to arthritis. Further tests revealed plasma cell leukemia, highlighting the importance of thorough diagnostic workups.
According to the National Cancer Institute, the median survival rate for plasma cell leukemia is about 11 months, though outcomes vary based on individual factors and treatment responses.
Many confuse plasma cell leukemia with chronic lymphocytic leukemia (CLL), another blood cancer. Unlike CLL, which primarily affects lymphocytes, plasma cell leukemia targets plasma cells specifically.
Another misconception is that plasma cell leukemia is always secondary. While most cases develop from multiple myeloma, primary plasma cell leukemia does occur, though less frequently.